Sandostatin Related Published Studies
Well-designed clinical trials related to Sandostatin (Octreotide)
Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. [2008.10]
Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial. [2008.08]
Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. [2008.04]
Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: Results of a prospective randomized double-blinded placebo-controlled trial. [2008.02.23]
Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial. [2007.10]
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. [2007.09.03]
Comparison of Octreotide and Standard Therapy Versus Standard Therapy Alone for the Treatment of Sulfonylurea-Induced Hypoglycemia. [2007.08.29]
Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. [2007.08.15]
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. [2007.07]
Octreotide Enhances Portal Pressure Reduction Induced by Propranolol in Cirrhosis: A Randomized, Controlled Trial. [2007.06.29]
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. [2007.06.21]
Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. [2007.05]
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. [2007.03]
Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. [2007.02]
Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome. [2007.01.19]
Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. [2007.01]
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. [2007.01]
Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. [2007.01]
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. [2006.12]
Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. [2006.11]
Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves' Ophthalmopathy. [2006.09.19]
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. [2006.06]
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. [2006.04]
Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction. [2006.03]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2006.02]
Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. [2006.02]
Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. [2005.10]
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. [2005.10]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2005.09.13]
Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy. [2005.09]
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. [2005.08]
Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy. [2005.08]
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. [2005.08]
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. [2005.07]
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. [2005.07]
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. [2005.07]
The use of low dose octreotide prophylaxis in pancreatic transplants with enteric drainage. Results of a prospective randomized single center trial. [2005.06]
The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. [2005.04]
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. [2005.03]
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. [2005.03]
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. [2005.02]
Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. [2005.01]
Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. [2005.01]
Octreotide is not effective in the acute treatment of migraine. [2005.01]
Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. [2004.12]
Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. [2004.10]
[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections] [2004.07]
Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. [2004.05]
[Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study] [2004.03]
The effect of octreotide as an adjunct treatment in active nonvariceal upper gastrointestinal bleeding. [2004.03]
Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis. [2004.03]
Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. [2004.03]
[Effects of acute octreotide infusion on renal function in patients with cirrhosis and portal hypertension] [2004.02]
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. [2004.02]
Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. [2004.01.01]
[The effects of octreotide on portal hemodynamics in patients with liver cirrhosis] [2004.01]
The somatostatin analogue octreotide impairs sleep and decreases EEG sigma power in young male subjects. [2004.01]
Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. [2003.10]
Long-term effects of octreotide therapy on in-stent restenosis. [2003.07]
Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2003.07]
Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. [2003.06]
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. [2003.05]
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. [2003.04]
Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. [2003.03]
The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. [2002.09.01]
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. [2002.09]
Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. [2002.09]
Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. [2002.08]
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. [2002.07]
Effect of short-term octreotide therapy and total parenteral nutrition on the development of biliary sludge and lithiasis. [2002.05]
Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. [2002.04]
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. [2002.04]
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. [2002.04]
Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. [2002.04]
Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. [2002.03]
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). [2002.03]
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. [2002.01.15]
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. [2002.01]
Efficacy of octreotide in the control of acute upper gastrointestinal bleeding. [2001.12]
The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. [2001.11]
Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. [2001.09]
Validation of color Doppler EUS for azygos blood flow measurement in patients with cirrhosis: application to the acute hemodynamic effects of somatostatin, octreotide, or placebo. [2001.07]
Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. [2001.07]
Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease. [2001.06]
[Effect of octreotide on intragastric pH in patients with duodenal ulcer bleeding] [2001.05.10]
Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. [2001.05]
A comparison of insulin suppression tests performed with somatostatin and octreotide with particular reference to tolerability. [2001.03]
Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis. [2001.02]
Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. [2001.02]
[Gabexate mesilate vs gabexate mesilate combined with octreotide in the prevention of postoperative complications of pancreatic surgery: preliminary results] [2001.01]
Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. [2001.01]
Octreotide for cancer of the liver and biliary tree. [2001]
Octreotide treatment in patients with severe acute pancreatitis. [2000.11]
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. [2000.11]
Endoscopic injection therapy vs. multipolar electrocoagulation vs. laser vs. injection + octreotide vs. injection + omeprazole in the treatment of bleeding peptic ulcers. A prospective randomized study. [2000.09]
Octreotide in acute bleeding esophageal varices: a prospective randomized study. [2000.09]
Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. [2000.09]
Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. [2000.09]
Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. [2000.09]
48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. [2000.05]
Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. [2000.05]
|
